SCHEMBL1980862

SCHEMBL1980862

O=C1Nc2ccccc2/C1=C\c1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 7/20 1.00
RET P07949 5/20 1.00
FLT3 P36888 5/20 1.00
CDK7 P50613 4/20 1.00
AURKB Q96GD4 4/20 1.00
KDR P35968 4/20 1.00
PRKD3 O94806 3/20 1.00
PDGFRB P09619 3/20 1.00
LTK P29376 3/20 1.00
CSNK1A1 P48729 3/20 1.00
MAP2K1 Q02750 3/20 1.00
MST1R Q04912 3/20 1.00
NTRK3 Q16288 3/20 1.00
NTRK2 Q16620 3/20 1.00
CLK4 Q9HAZ1 3/20 1.00
ALK Q9UM73 3/20 1.00
CDK5 Q00535 3/20 1.00
ABL1 P00519 2/20 1.00
DAPK3 O43293 2/20 1.00
MAP4K4 O95819 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14448886 1.00 NTRK1 (1.00) NTRK1RETFLT3CDK7AURKB
SCHEMBL1980864 1.00 NTRK1 (1.00) NTRK1RETFLT3CDK7AURKB
SCHEMBL5476209 0.84 FLT3 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL14448917 0.84 LRRK2 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL14448936 0.84 NTRK1 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL5473156 0.84 NTRK1 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL5465281 0.84 NTRK1 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL5464546 0.84 LRRK2 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL8468388 0.84 NTRK1 (0.73) NTRK1RETFLT3CDK7AURKB
SCHEMBL5472578 0.84 NTRK1 (0.73) NTRK1RETFLT3CDK7AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130344165-A1 JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-12-26 US claimed
WO-2012116137-A2 JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2012-08-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20030108946-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2003-06-12 US claimed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP claimed
US-20020022626-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease TANG PENG CHO (US) 2002-02-21 US claimed
EP-0929520-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE Sugen, Inc. (US) 1999-07-21 EP claimed
WO-1998007695-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE SUGEN, INC. (US) 1998-02-26 WO claimed
US-12377194-B2 JAB1 inhibitory compositions for ossification and methods related thereto EMORY UNIVERSITY (US) 2025-08-05 US disclosed
US-20220023506-A1 JAB1 Inhibitory Compositions for Ossification and Methods Related Thereto EMORY UNIVERSITY 2022-01-27 US disclosed
US-11179500-B2 JAB1 inhibitory compositions for ossification and methods related thereto EMORY UNIVERSITY (US) 2021-11-23 US disclosed
US-20130344165-A1 JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-12-26 US disclosed
WO-2012116137-A2 JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2012-08-30 WO disclosed
US-6147106-A USEFUL FOR THE TREATMENT OF DISEASES RELATED TO UNREGULATED PROTEIN KINASE SIGNAL TRANSDUCTION, INCLUDING CELL PROLIFERATIVE DISEASES SUCH AS CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS SUGEN, INC. (US) 2000-11-14 US disclosed
EP-0929520-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE Sugen, Inc. (US) 1999-07-21 EP disclosed
EP-0929520-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE Sugen, Inc. (US) 1999-07-21 EP disclosed
WO-1998007695-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE SUGEN, INC. (US) 1998-02-26 WO disclosed
WO-1998007695-A1 INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE SUGEN, INC. (US) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022626-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NTRK1 248/4885RET 286/4885FLT3 370/4885
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NTRK1 175/4885RET 3720/4885FLT3 4311/4885
US-20030108946-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NTRK1 248/4885RET 286/4885FLT3 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.